HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025MIRAMAR, Fla., June 04, 2025 (GLOBE ...

HCW Biologics ( ($HCWB) ) just unveiled an update. On June 4, 2025, HCW Biologics announced that WY Biotech completed its due diligence on the ...

HCW Biologics Inc. and WY Biotech Co., Ltd. have finalized a licensing agreement for the development and commercialization of HCW11-006, a novel immunotherapy targeting age-related diseases and ...

MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical ...

MIRAMAR, Fla. - HCW Biologics Inc. (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company currently trading at $6.70 per share with a market capitalization of $303 million ...

HCW Biologics Inc., (NASDAQ: HCWB) began Wednesday trading deep in the red. The Miramar, Fla.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies ...

MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and ...

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the ...